• For Institutions

  • Download
  • Help
  • About

longbridgelongbridge
longbridgelongbridge
Products
Pricing
Markets
Global Markets
Stock Screener
Information
Insights
News
Live
Academy
Affiliate Program
Promotions
PortAI
EN
English
简体中文
繁體中文
繁體中文(廣東話)Posts & comments will be shown in Cantonese
Search...
Quote ListQuote List
Overview
News
Financials
© 2025 Longbridge|Disclaimer

Event Tracking

Nov12
Oppenheimer Analyst Maintains Buy Rating on Keros Therapeutics
13:02
Nov6
H.C. Wainwright Reiterates Buy Rating on Keros Therapeutics
11:51
Keros Therapeutics released FY2025 Q3 earnings on November 5 (EST), actual revenue USD 14.26 M (forecast USD 4.222 M), actual EPS USD -0.18 (forecast USD -1.02)
04:00
Keros Therapeutics released FY2025 9 Months Earnings on November 5 (EST), actual revenue USD 243.68 M, actual EPS USD 2.68
04:00
Oct20
Keros Therapeutics Launches Stock Repurchase Program
14:02
Aug7
Keros Therapeutics released FY2025 Semi-Annual earnings on August 6 (EST), actual revenue USD 229.41 M, actual EPS USD 2.86
03:00

Schedules & Filings

Schedules
Filings
Nov5
Earning Release(EST)

FY2025 Q3 Earning Release (USD) Revenue 14.26 M, Net Income -7.28 M, EPS -0.18

Aug6
Earning Release(EST)

FY2025 Q2 Earning Release (USD) Revenue 18.17 M, Net Income -30.7 M, EPS -0.7599

May6
Earning Release(EST)

FY2025 Q1 Earning Release (USD) Revenue 211.25 M, Net Income 148.45 M, EPS 3.62

View More

Stock List

Top Gainers
Top Decliners
China Concepts
Symbol
Price
%Chg
Change
BBGI
16.690
+312.10%
+12.640
SRV.RT
0.0900
+111.76%
+0.048
BEAT
1.550
+92.43%
+0.745
ENVB
10.330
+74.49%
+4.410
BDRX
6.720
+65.11%
+2.650
ASPC
16.810
+60.40%
+6.330
IRBT
5.240
+48.44%
+1.710
CGTL
0.9727
+47.40%
+0.313
MIGI
6.700
+45.65%
+2.100
PLAB
37.350
+45.39%
+11.660
View More